Business Context and Reporting Period
This Form 8-K was filed by Obalon Therapeutics, Inc. (trading symbol: OBLN) on February 7, 2020. The report details a material definitive agreement entered into on February 5, 2020, with Lincoln Park Capital Fund, LLC. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics and Transaction Details
- Commitment Amount: Lincoln Park has committed to purchase up to $15.0 million of the Company's common stock.
- Transaction Structure: The agreement allows the Company to sell shares at its sole discretion over a 36-month period following the effectiveness of a registration statement.
- Purchase Limits:
- Regular Purchase: Up to 150,000 shares per business day.
- Increased Limits: Up to 200,000 shares if the closing price is $\ge$ $2.00; up to 250,000 shares if the closing price is $\ge$ $3.00.
- Maximum per Transaction: $1,000,000.
- Exchange Cap: Issuances are limited to 19.99% of shares outstanding prior to execution (1,545,553 shares based on 7,731,633 outstanding shares), unless stockholder approval is obtained or the average sale price exceeds $1.79 per share.
- Beneficial Ownership Limit: Lincoln Park cannot beneficially own more than 9.99% of the Company's common stock.
- Upfront Cost: The Company paid $150,000 in cash to Lincoln Park for due diligence and transaction expenses.
- Use of Proceeds: Expected to be used for working capital and general corporate purposes.
Note: This filing does not provide specific revenue, profit, cash flow, or debt figures for the reporting period.
Material Changes Versus Prior Period
The new Purchase Agreement replaces a prior agreement dated December 27, 2018, under which Lincoln Park had committed to purchase up to $20.0 million of common stock. The prior agreement was terminated effective February 5, 2020, reducing the total committed capital availability from $20.0 million to $15.0 million.
Guidance, Outlook, and Risks
- Management Commentary: Actual sales of shares will depend on market conditions, trading prices, and the Company's funding determinations. The Company retains the right to terminate the agreement at any time without cost or penalty.
- Restrictions: The Company is restricted from entering into "variable rate" transactions with third parties for a defined period. Lincoln Park is prohibited from short selling or hedging the Company's shares.
- Risks and Contingencies: The filing includes standard forward-looking statement disclaimers regarding uncertainties in product research and development. The agreement automatically terminates in the event of bankruptcy proceedings by or against the Company.
- Regulatory Status: Securities are being sold under Section 4(a)(2) and Rule 506(b) exemptions. A registration statement must be filed and declared effective by the SEC before sales can commence.
Key Facts for Investor Verification
- Verify the effectiveness date of the registration statement required to commence sales under the new agreement.
- Monitor the Company's stock price relative to the $2.00 and $3.00 thresholds that trigger increased daily purchase limits.
- Track the 9.99% beneficial ownership cap for Lincoln Park to determine if it limits future capital raises under this facility.
- Review the Company's most recent Form 10-Q (filed November 8, 2019) for detailed financial position and liquidity status, as this 8-K does not contain financial statements.
- Confirm whether the Company intends to seek stockholder approval to exceed the 19.99% Exchange Cap if necessary.